| Literature DB >> 28187201 |
Valérie Pittet1, Carla Vaucher1, Florian Froehlich2,3, Bernard Burnand1, Pierre Michetti4, Michel H Maillard2.
Abstract
BACKGROUND: Patient-reported disease perceptions are important components to be considered within a holistic model of quality of care. Gender may have an influence on these perceptions. We aimed to explore gender-specific concerns of patients included in a national bilingual inflammatory bowel disease cohort.Entities:
Mesh:
Year: 2017 PMID: 28187201 PMCID: PMC5302448 DOI: 10.1371/journal.pone.0171864
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline patient characteristics.
Values are number and percentages unless otherwise specified.
| Variables | All (N) | Men | Women | p-value |
|---|---|---|---|---|
| 1102 | 504 (45.7) | 598 (54.3) | ||
| 761 | 365 (72.4) | 396 (66.2) | 0.027 | |
| 47.5 (15.2) | 48.7 (15.7) | 46.5 (14.7) | 0.017 | |
| <0.001 | ||||
| 100 | 37 (7.9) | 63 (11.0) | ||
| 411 | 165 (35.0) | 246 (43.0) | ||
| 166 | 59 (12.5) | 107 (18.7) | ||
| 214 | 123 (26.1) | 91 (15.9) | ||
| 152 | 87 (18.5) | 65 (11.4) | ||
| <0.001 | ||||
| 743 | 357 (74.8) | 386 (68.7) | ||
| 30 | 13 (2.7) | 17 (3.0) | ||
| 101 | 18 (3.8) | 83 (14.8) | ||
| 165 | 89 (18.7) | 76 (13.5) | ||
| 31.8 (13.8) | 33.2 (14.4) | 30.6 (13.2) | 0.003 | |
| 15.7 (10.2) | 15.6 (10.3) | 15.9 (10.1) | 0.518 | |
| 0.027 | ||||
| 596 | 256 (50.8) | 340 (56.9) | ||
| 475 | 228 (45.2) | 247 (41.3) | ||
| 31 | 20(4.0) | 11 (1.8) | ||
| 0.320 | ||||
| 186 | 86 (33.6) | 100 (29.4) | ||
| 209 | 93 (36.3) | 116 (34.1) | ||
| 168 | 65 (25.4) | 103 (30.3) | ||
| 14 | 7 (2.7) | 7 (2.1) | ||
| 0.325 | ||||
| 294 | 118 (46.1) | 176 (51.8) | ||
| 198 | 88 (34.4) | 110 (32.3) | ||
| 104 | 50 (19.5) | 54 (15.9) | ||
| 0.115 | ||||
| 117 | 48 (19.3) | 69 (26.7) | ||
| 207 | 113 (45.6) | 94 (36.4) | ||
| 172 | 83 (33.5) | 89 (34.5) | ||
| 235 | 106 (21.0) | 129 (21.6) | 0.827 | |
| 0.891 | ||||
| 14 | 5 (1.0) | 9 (1.5) | ||
| 232 | 105 (20.8) | 127 (21.2) | ||
| 340 | 157 (31.1) | 183 (30.6) | ||
| 516 | 237 (47.0) | 279 (46.7) | ||
| 287 | 135 (26.8) | 152 (25.4) | 0.606 | |
| 585 | 238 (47.2) | 347 (58.0) | <0.001 | |
| <0.001 | ||||
| 761 | 376 (78.2) | 385 (65.8) | ||
| 305 | 105 (21.8) | 200 (34.2) | ||
| 0.663 | ||||
| 903 | 410 (85.2) | 493 (84.3) | ||
| 163 | 71 (14.8) | 92 (15.7) | ||
| 49.4 (9.2) | 51.0 (8.1) | 48.2 (9.9) | <0.001 | |
| 46.6 (10.6) | 48.3 (9.7) | 45.1 (11.1) | <0.001 | |
| 57.7 (9.8) | 59.7 (8.8) | 56.1 (10.2) | <0.001 |
* Mean (SD).
CD, Crohn’s disease; UC, ulcerative colitis; IBDU, inflammatory bowel disease—undetermined; GI, gastrointestinal; 5-ASA, 5-aminosalicylic acid; IBDQ, Inflammatory Bowel Disease Questionnaire.
Mean, median, and interquartile range (IQR) scores for each concern according to gender, type of diagnosis, language, and age.
| Dimension | Mean | Median (IQR) |
|---|---|---|
| Loss of bowel control | 61.8 | 70 (38–92) |
| Developing cancer | 61.1 | 69 (44–88) |
| Link between stress and disease | 60.3 | 68 (44–86) |
| Chronicity of the disease | 60.1 | 66 (43–85) |
| Fatigue | 58.5 | 65 (31–88) |
| Having to take life-long treatments | 55.8 | 64 (23–87) |
| Uncertain nature of the disease | 57.7 | 63 (34–85) |
| Treatment side effects | 54.5 | 63 (20–84) |
| Difficulty in predicting relapses | 54.6 | 58 (28–82) |
| Ability of children to develop the same disease | 55.7 | 58 (25–88) |
| Having surgery | 54.2 | 57 (20–86) |
| Energy level | 53.1 | 56.5 (21–79) |
| Having an ostomy bag | 51.9 | 52 (14–87) |
| Being addicted to medications | 49.5 | 52 (14–81) |
| Pain | 49.3 | 51 (19–76) |
| Influence of the disease on physical and sports performance | 47.7 | 51 (15–74) |
| Origins of the disease | 47.4 | 51 (13–76) |
| Ability to achieve full potential | 45.3 | 49 (12–71) |
| Feeling out of control | 43.8 | 47 (8–75) |
| Impact on sexual life | 43.6 | 47 (10–70) |
| Loss of sexual drive | 40.3 | 44 (6–67) |
| Diet | 41.5 | 43.5 (9–68) |
| Medical consultations and exams | 40.7 | 41 (11–67) |
| Intimacy | 38.7 | 37.5 (7–62) |
| Dying early | 39.4 | 35 (8–65) |
| Support by relatives | 36.1 | 34 (6–54) |
| Being a burden on others | 39.2 | 32 (6–69) |
| Professional future | 36.9 | 29 (6–62) |
| Having access to quality medical care | 37.7 | 28 (7–66) |
| Attractiveness | 35.9 | 28 (5–62) |
| Feeling alone | 33.0 | 19.5 (5–54) |
| Feeling "dirty" or "smelly" or producing unpleasant odors | 34.1 | 19 (4–62) |
| Financial difficulties | 30.4 | 16 (4–52) |
| Ability to have children | 30.3 | 15 (3–50) |
| Being treated as different | 27.1 | 14 (4–49) |
| Having to talk about disease with relatives | 27.3 | 14 (4–49) |
| Passing disease on to others | 32.9 | 14 (3–57) |
| 45.3 |
Results of the rotated factor matrix.
| Dimensions | ||||||
|---|---|---|---|---|---|---|
| Concerns | Socialization and stigmatization | Constraints and uncertainty | Symptoms (impact on body and mind) | Loss of body control (including sexuality) | Disease transmission | Long-term impact |
| Feeling alone | 0.10 | 0.25 | 0.18 | 0.07 | 0.20 | |
| Being treated as different | 0.11 | 0.14 | 0.23 | 0.07 | 0.19 | |
| Intimacy | 0.14 | 0.25 | 0.16 | 0.11 | ||
| Support by relatives | 0.16 | 0.26 | 0.15 | 0.10 | 0.11 | |
| Being a burden on others | 0.19 | 0.33 | 0.28 | 0.12 | 0.01 | |
| Professional future | 0.23 | 0.12 | 0.01 | 0.06 | ||
| Financial difficulties | 0.22 | 0.27 | 0.05 | 0.04 | 0.02 | |
| Having access to quality medical care | 0.23 | 0.12 | 0.08 | 0.16 | 0.18 | |
| Having to talk about disease with relatives | 0.21 | 0.03 | 0.12 | -0.05 | 0.01 | |
| Feeling "dirty" or "smelly" or producing unpleasant odors | 0.02 | 0.12 | 0.13 | 0.14 | ||
| Attractiveness | 0.20 | 0.31 | 0.24 | 0.21 | 0.04 | |
| Diet | 0.32 | 0.26 | 0.19 | 0.08 | 0.00 | |
| Having to take life-long treatments | 0.18 | 0.09 | 0.09 | 0.09 | 0.09 | |
| Chronicity of the disease | 0.16 | 0.19 | 0.27 | 0.03 | 0.07 | |
| Treatment side effects | 0.14 | 0.19 | 0.02 | 0.04 | 0.11 | |
| Uncertain nature of the disease | 0.17 | 0.17 | 0.32 | 0.13 | 0.27 | |
| Being addicted to medications | 0.15 | 0.13 | 0.07 | 0.13 | 0.19 | |
| Origins of the disease | 0.19 | 0.12 | 0.12 | 0.19 | 0.30 | |
| Energy level | 0.25 | 0.17 | 0.25 | 0.10 | 0.13 | |
| Fatigue | 0.25 | 0.28 | 0.19 | 0.14 | 0.05 | |
| Ability to achieve full potential | 0.21 | 0.13 | 0.04 | 0.23 | ||
| Influence of the disease on physical and sports performance | 0.30 | 0.22 | 0.24 | 0.10 | 0.10 | |
| Pain | 0.34 | 0.21 | 0.14 | 0.02 | ||
| Link between stress and disease | 0.23 | 0.33 | 0.15 | 0.12 | 0.17 | |
| Loss of bowel control | 0.21 | 0.30 | 0.24 | 0.14 | 0.10 | |
| Feeling out of control | 0.14 | 0.19 | 0.13 | 0.16 | ||
| Impact on sexual life | 0.17 | 0.33 | 0.11 | -0.04 | ||
| Difficulty in predicting relapses | 0.21 | 0.28 | 0.14 | 0.11 | ||
| Loss of sexual drive | 0.07 | 0.32 | 0.15 | 0.12 | ||
| Having surgery | 0.20 | 0.11 | 0.12 | 0.26 | ||
| Having an ostomy bag | 0.16 | 0.17 | 0.14 | 0.18 | 0.31 | |
| Passing disease on to others | 0.16 | 0.10 | 0.09 | 0.14 | 0.18 | |
| Ability of children to develop the same disease | 0.06 | 0.22 | 0.14 | 0.20 | 0.12 | |
| Developing cancer | 0.08 | 0.10 | 0.24 | 0.14 | ||
| Dying early | 0.22 | 0.26 | 0.14 | 0.10 | 0.11 | |
| Medical consultations and exams | 0.31 | 0.34 | 0.11 | 0.07 | 0.09 | 0.08 |
| Ability to have children | - | - | - | - | - | |
Fig 1Median for individual concerns related to symptoms according to gender.
Fig 2Median for individual concerns related to socialization and stigmatization according to gender.
Fig 3Median for individual concerns related to loss of body control according to gender.
Fig 4Median for individual concerns related to constraints and uncertainty according to gender.
Multiple linear regressions for each concern dimension stratified by gender.
Values indicate the direction of the association and the p-value.
| Socialization and stigmatization | Constraints and uncertainty | Symptoms (impact on body and mind) | Loss of body control (including sexuality) | |||||
|---|---|---|---|---|---|---|---|---|
| Men | Women | Men | Women | Men | Women | Men | Women | |
| Age >40 years | - / 0.014 | |||||||
| French speakers | - / 0.023 | - / <0.001 | + / 0.042 | |||||
| Occupation | ||||||||
| ref | ||||||||
| - / 0.230 | ||||||||
| + / 0.004 | ||||||||
| + / 0.867 | ||||||||
| Disease duration | ||||||||
| ref | ||||||||
| - / 0.137 | ||||||||
| - / 0.015 | ||||||||
| Symptom severity | + / <0.001 | + / <0.001 | + / <0.001 | + / 0.014 | + / <0.001 | + / <0.001 | + / <0.001 | + / 0.001 |
| Highest treatment line | ||||||||
| ref | ref | ref | ||||||
| + / 0.042 | + / 0.075 | + / 0.268 | ||||||
| + / 0.020 | + / 0.024 | + / 0.189 | ||||||
| + / 0.007 | + / 0.009 | + / 0.078 | ||||||
| History of resection surgery | + / 0.026 | - / 0.001 | ||||||
| History of extraintestinal manifestations | + / 0.014 | |||||||
| Signs of anxiety | ||||||||
| ref | ref | ref | ref | ref | ref | |||
| + / 0.039 | + / <0.001 | + / 0.005 | + / 0.261 | + / 0.001 | + / 0.001 | |||
| + / 0.061 | + / <0.001 | + / 0.005 | + / 0.007 | + / <0.001 | + / <0.001 | |||
| + / 0.047 | + / <0.001 | + / <0.001 | + / 0.018 | + / <0.001 | + / <0.001 | |||
| Signs of depression | ||||||||
| ref | ref | |||||||
| + / 0.001 | + / <0.001 | |||||||
| + / 0.104 | + / 0.007 | |||||||
| + / 0.441 | + / 0.543 | |||||||
| SF-36 MCS | - / 0.043 | |||||||
| SF-36 PCS | - / 0.003 | - / <0.001 | ||||||
| IBDQ bowel | + / 0.035 | |||||||
| IBDQ social | - / 0.015 | - / <0.001 | ||||||
| Task coping | + / 0.002 | |||||||
| Emotional coping | + / 0.025 | + / 0.005 | + / 0.006 | + / 0.013 | + / <0.001 | + / 0.015 | ||
| Avoidance coping | - / 0.031 | |||||||
* Component unrelated to anxiety and depression.
5-ASA, 5-aminosalicylic acid; MCS, Mental Component Summary; PCS, Physical Component Summary; IBDQ, Inflammatory Bowel Disease Questionnaire.